FDA Bulk Drug Substances Lists for 503A and 503B, Explained

What a bulk drug substance is

Bulk drug substance

An active pharmaceutical ingredient, the substance that provides pharmacological activity, used to compound a finished preparation. It is distinct from inactive ingredients and from the finished compounded product. ¹

When a pharmacy or outsourcing facility compounds from a raw active ingredient rather than starting from an approved finished drug, the question of which bulk substances are permitted comes into play. Sections 503A and 503B of the federal law each address this, and the FDA maintains public information about the substances under consideration and their status. ¹²

Why there are separate 503A and 503B treatments

Because 503A pharmacies and 503B outsourcing facilities operate under different parts of the law, the way bulk substances are handled is not identical between them. ¹² The two-lane structure created by the Drug Quality and Security Act carries through here: the conditions, categories, and FDA materials associated with each section are tracked separately. A pharmacy should confirm which framework applies to its operation.

How nomination and review work, in plain terms

The lists are not static. Substances can be nominated for consideration, the FDA reviews them, and substances are sorted based on that review. ¹ At a high level the process looks like this, though the official FDA pages carry the binding detail and current status.

• Nomination. Interested parties submit substances for FDA consideration, with supporting information. ¹
• Review. The FDA evaluates nominated substances, sometimes with input from its advisory committee on compounding. ¹
• Categories. Substances are placed into categories that reflect their status during and after review. The category names and meanings are defined by the FDA and can change. ¹²
• Updates. The FDA revises these materials over time, so a substance status is a snapshot, not a permanent label. ¹²

Why this matters for marketing

For a compounding pharmacy, the safest marketing posture is to talk about credibility, sourcing discipline, and adherence to current rules, not to advertise specific substances as if they were approved products. ³ Because the underlying lists shift, marketing copy that names substances can become inaccurate quickly, which is both a compliance and a trust problem. Education that points readers to primary sources ages far better.

None of this is a clinical statement about any substance. Which ingredients are appropriate for a given patient is a decision for the licensed prescriber, and which substances may be lawfully used is governed by the current FDA framework. ¹²